Skip to main content
. Author manuscript; available in PMC: 2026 Sep 19.
Published in final edited form as: Int J Tuberc Lung Dis. 2025 Oct 31;29(11):495–500. doi: 10.5588/ijtld.24.0637

Table 3.

Pharmacokinetic measurements of delamanid after 8 weeks of treatment with delamanid in 49 participants treated for MDR-TB.

HIV-negative, n = 30 median (IQR) HIV-positive, n = 19 median (IQR) Geometric mean ratio (90% CI)
AUC0–23, mg·h/L 5.68 (4.90–6.85) 4.89 (3.86–6.40) 1.08 (0.92–1.27)
Cmax, mg/L 0.35 (0.26–0.44) 0.27 (0.22–0.33) 1.27 (0.79–2.06)
Tmax, h 4 (0–23) 4 (0–4) —

Median with interquartile range is shown in brackets, where appropriate.

CI = confidence interval; IQR = interquartile range; MDR-TB = multidrug-resistant TB.